General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. Opening Hook
Supriya Lifescience walked into its earnings call with a record quarter: ₹277 crore revenue, up 50% YoY. The catch? Management casually mentioned geopolitical disruptions cost them ~₹10 crore that same quarter—meaning the headline number dodges an unstated counterfactual. EBITDA margin hit 35.5%, surpassing their own 33–35% guidance. But the real story lurking in the footnotes: working capital days ballooned to 170, up from 158 a year prior. All the growth in the world rings hollow if cash gets stuck in inventory and receivables.
2. At a Glance
- Q4 Revenue: ₹277 cr – Record quarter, +50% YoY; ~₹10 cr headwind impact baked in.
- Q4 EBITDA Margin: 35.5% – Surpassed guided 33–35% range.
- FY26 Revenue: ₹828 cr – +19% YoY, broadly in line with management’s ~20% guidance.
- FY26 EBITDA Margin: 35.5% – Again, beat the range.
- PAT Growth: +11% (FY26 at ₹209 cr) – Slower than revenue, tax rate normalized at ~24–25%.
- Working Capital Days: 170 – Up 16 days YoY; CFO expects “170–180 stable state.”
- Backward Integration: 76% (FY26) – Inventory build from larger products pinching cash.
3. Management’s Key Commentary
On the VAI outcome:
“We received EIR with Voluntary Action Indicated; inspection covered 7 blocks, only one minor observation proactively addressed, reinforcing robust quality system and adherence to cGMP standards.”
Translation: The FDA found something minor, we fixed it before they officially asked. “Voluntary Action Indicated” is FDA-speak for “do better”—not a free pass, not a showstopper, just a footnote.
On margin outperformance:
“We’re surpassing our guided range of 33% to 35%.”
Translation: We beat our own target. Management then immediately reiterated the same 33–35% guidance for forward years.
On US market entry timing:
“The current portfolio inherently does not have a very large market in the U.S. Expect higher US relevance over 3–4 years as newer launches scale.”
Translation: We’re not in the US market now. Three to four years is industry-speak for “we’ll revisit this slide in 2029.”
On new product mix and margins:
“New products initially scale in semi-regulated markets at lower realizations, then mature into regulated markets over 2–3 years…we’re continuously adding 3–4 molecules/year.”
Translation: We launch cheap, let them ripen, then sell them dear. But we keep launching new cheap ones, so the blended margin never quite rips.
On the Patalganga capex behemoth:
“Need to be prepared for when these products scale…a lot of larger companies want to tie up with us for basket kind of products.”
Translation: CMOs are calling. We’re building factories now so we can say yes later.
On DSM/riboflavin scale-up:
“Volumes stabilized at ~3 tons/month; expected peak ~₹60
